Registration - Consultant

Canadian Biosimilars Forum / Forum canadien des biosimilaires / Ross Wallace, Consultant

Registration Information

Client name: Canadian Biosimilars Forum / Forum canadien des biosimilaires
Lobbyist name: Ross Wallace, Consultant
Initial registration start date: 2016-11-22
Registration status: Inactive
Registration Number: 929211-358995

Associated Communications

Total Number of Communication Reports: 4

Monthly communication reports in the last 6 months: 0

Version 2 of 5 (2017-06-04 to 2017-11-02)

Registration versions:

Version 2 of 5 (2017-06-04 to 2017-11-02)

Lobbying Information

Subject Matters

Health
Intellectual Property
Research and Development
Science and Technology

Subject Matter Details

Policies or Program

The evolving policy framework relating to the regulation and reimbursement of biologic pharmaceuticals broadly, and biosimilars in particular.

Communication Techniques

Written communication
Oral communication

The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.

Government Institutions

Health Canada (HC)
Patented Medicine Prices Review Board (PMPRB)

Client Details

Government funding

No government funding was received during the last completed financial year.

Client Contact Information

Address:
P.O Box 47099 Dundas Sq PO
Toronto, ON M5B 2G0
Canada

Telephone number: 416-613-5052

Client representative

Nadia Turchetta, Co-Chair

Parent Company Information

Canadian Biosimilars Forum / Forum canadien des biosimilaires is not a subsidiary of any other parent companies.

Coalition Members Information

Amgen Canada
- 6775 Financial Drive Suite 100
  Mississauga, ON L5N 0A4
  Canada
Merck Canada
- 250-101 College Street
  Toronto, ON M5G 1L7
  Canada
Pfizer Canada
- 17300 Trans-Canada Rte
  Kirkland, QC H4P 1H7
  Canada
Sandoz Canada
- 110 de Lauzon
  Boucherville, QC J4B 1E6
  Canada
Teva Canada
- 30 Novopharm Ct.
  Toronto, ON M1B 2K9
  Canada

Individual, organization or corporation with a Direct Interest Beneficiary Information

The activities of Canadian Biosimilars Forum / Forum canadien des biosimilaires are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.

Subsidiary Beneficiary Information

Canadian Biosimilars Forum / Forum canadien des biosimilaires does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyist Details

Ross Wallace | No public offices held

Business address:
655 Bay Street, Suite 401
Toronto, ON M5G 2K4
Canada

Telephone number: 416-888-6553

Consultant Firm and Address

Firm: Santis Health

Address:
655 Bay Street, Suite 401
Toronto, ON M5G 2K4
Canada

Telephone number: 416-888-6553

Canadian Biosimilars Forum/Forum canadien des biosimilaires

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Canadian Biosimilars Forum/Forum canadien des biosimilaires	2016-11-22	2021-02-16

Canadian Biosimilars Forum / Forum canadien des biosimilaires

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)

Ross Wallace, Santis Health (Consultant)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15^th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-4 of 4

Canadian Biosimilars Forum
Consultant: Ross Wallace

Designated Public Office Holders who participated in the communication:
- Cathy Parker, Director General | Health Products and Therapeutics Branch | Health Canada (HC)
- Kelly Robinson, Director | Health Products and Therapeutics Branch | Health Canada (HC)
- Anthony Ridgway, Senior Regulatory Scientist | Health Products and Therapeutics Branch | Health Canada (HC)
- Agnes Klein, Senior Medical Advisor | Health Products and Therapeutics Branch | Health Canada (HC)
- Georgette Roy, Director, Office of Regulatory Affairs | Health Products and Therapeutics Branch | Health Canada (HC)
- Liz Anne Gillham-Eisen, A Director | Health Products and Therapeutics Branch | Health Canada (HC)
- Stephanie Hardy, Manager, Policy Unit | Health Products and Therapeutics Branch | Health Canada (HC)
- Jian Wang, Division Chief | Health Products and Therapeutics Branch | Health Canada (HC)
- Lindsay Elmgren, Director, Centre for Biologics Evaluation | Health Products and Therapeutics Branch | Health Canada (HC)
- Emily Griffiths, Subject Matter / Technical Specialist | Health Products and Therapeutics Branch | Health Canada (HC)
- Michele Chadwick, Manager | Health Products and Therapeutics Branch | Health Canada (HC)
- Megan Bettle, Director | Health Products and Therapeutics Branch | Health Canada (HC)
- Johanne Veenstra, Senior Regulatory Officer | Health Products and Therapeutics Branch | Health Canada (HC)
- Evelyn Soo, Associate to the Director General | Health Products and Therapeutics Branch | Health Canada (HC)
- Jemma Fraije, A/ Regulatory Affairs Supervisor | Health Products and Therapeutics Branch | Health Canada (HC)
- Karen Reynolds, Executive Director | Strategic Policy Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2018-05-22
Posted date: 2018-06-15
Communication number: 358995-429091 View associated registration
Canadian Biosimilars Forum
Consultant: Ross Wallace

Designated Public Office Holders who participated in the communication:
- Cathy Parker, Director General | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Anthony Ridgway, Acting Director | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Agnes Klein, Senior Medical Advisor, DGO | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Jeffrey Skene, Division Chief | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Wallace Lauzon, Division Chief | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Jian Wang, Division Chief | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Georgette Roy, Director | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Sandra Alderdice, Regulatory Affairs Supervisor | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Liz Anne Gillham-Eiosen, A Director | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Stephanie Hardy, Manager, Policy Unit | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Parag Buch, Subject Matter Technical Special | MARKETED HEALTH PRODUCTS DIRECTORATE | Health Canada (HC)
- Andrea Bedard, Policy Analyst | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Michele Chadwick, Manager | BIOLOGICS AND GENETIC THERAPIES DIRECTORATE | Health Canada (HC)
- Laura Johnson, SBD Project Manager | THERAPEUTIC PRODUCTS DIRECTORATE | Health Canada (HC)
- Alain Musende, Manager | MARKETED HEALTH PRODUCTS DIRECTORATE | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2017-11-21
Posted date: 2018-01-17
Communication number: 358995-418390 View associated registration
Canadian Biosimilars Forum
Consultant: Ross Wallace

Designated Public Office Holders who participated in the communication:
- Cathy Parker, Director General | Health Products and Food Branch | Health Canada (HC)
- Anthony Ridgway, Acting Director | Health Products and Food Branch | Health Canada (HC)
- Agnes Klein, Senior Medical Advisor | Health Products and Food Branch | Health Canada (HC)
- Jeffrey Skene, Division Chief | Health Products and Food Branch | Health Canada (HC)
- Wallace Lauzon, Division Chief | Health Products and Food Branch | Health Canada (HC)
- Jian Wang, Division Chief | Health Products and Food Branch | Health Canada (HC)
- Catherine Njue, Biostatistician Advisor - Clinical Trials | Health Products and Food Branch | Health Canada (HC)
- Georgette Roy, Director, Office of Regulatory Affairs | Health Products and Food Branch | Health Canada (HC)
- Sandra Alderdice, Regulatory Affairs Supervisor | Health Products and Food Branch | Health Canada (HC)
- Liz Anne Gillham-Eisen, A/Director | Health Products and Food Branch | Health Canada (HC)
- Stephanie Hardy, Manager, Policy Unit | Health Products and Food Branch | Health Canada (HC)
- Nick Orphanos, Senior Policy Analyst | Health Products and Food Branch | Health Canada (HC)
- Emily Griffiths, Policy Analyst | Health Products and Food Branch | Health Canada (HC)
- Ashley Baer, Policy Analyst | Health Products and Food Branch | Health Canada (HC)
- Deryck Trehearne, Director General | Health Products and Food Branch | Health Canada (HC)
- Trish Larwill, Senior Policy Advisor | Health Products and Food Branch | Health Canada (HC)
- Michele Chadwick, Manager | Health Products and Food Branch | Health Canada (HC)
- Laura Johnson, SBD Project Manager | Health Products and Food Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2017-06-09
Posted date: 2017-08-04
Communication number: 358995-404276 View associated registration
Canadian Biosimilars Forum
Consultant: Ross Wallace

Designated Public Office Holders who participated in the communication:
- Catherine Parker, Director General | Health Products and Food Branch | Health Canada (HC)
- Anthony Ridgway, Acting Director | Health Products and Food Branch | Health Canada (HC)
- Agnes Klein, Director | Health Products and Food Branch | Health Canada (HC)
- Jeffrey Skene, Division Chief | Health Products and Food Branch | Health Canada (HC)
- Wallace Lauzon, Division Chief | Health Products and Food Branch | Health Canada (HC)
- Jian Wang, Division Chief | Health Products and Food Branch | Health Canada (HC)
- Catherine Njue, Biostatistician Advisor - Clinical Trials | Health Products and Food Branch | Health Canada (HC)
- Georgette Roy, Director, Office of Regulatory Affairs | Health Products and Food Branch | Health Canada (HC)
- Sandra Alderdice, Regulatory Affairs Supervisor | Health Products and Food Branch | Health Canada (HC)
- Liz Anne Gillham-Eisen, A/Director | Health Products and Food Branch | Health Canada (HC)
- Stephanie Hardy, Manager, Policy Unit | Health Products and Food Branch | Health Canada (HC)
- Bobby Chauhan, Senior Regulatory Officer | Health Products and Food Branch | Health Canada (HC)
- Andrea Bedard, Policy Analyst | Health Products and Food Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2016-11-22
Posted date: 2016-12-15
Communication number: 358995-391145 View associated registration

Date Modified:: 2024-04-04

Search and menus

Language selection

Registration - Consultant

Canadian Biosimilars Forum / Forum canadien des biosimilaires / Ross Wallace, Consultant

Registration Information

Associated Communications

Version 2 of 5 (2017-06-04 to 2017-11-02)

Version 2 of 5 (2017-06-04 to 2017-11-02)

Subject Matters

Subject Matter Details

Policies or Program

Communication Techniques

Government Institutions

Government funding

Client Contact Information

Client representative

Parent Company Information

Coalition Members Information

Individual, organization or corporation with a Direct Interest Beneficiary Information

Subsidiary Beneficiary Information

Consultant Firm and Address